Atlas Molecular Pharma receives EMA and FDA Orphan Drug Designation for Congenital Erythropoietic Porphyria with Asphalion support

by Asphalion

Atlas Molecular Pharma, a company specialized in the discovery and development of first-in-class, innovative therapeutics for the treatment of Rare and ultra-Rare Diseases, announced that its candidat...

Read more
Subscribe to Directory
Write an Article

Recent News

Tuneable reverse photochromes in the sol...

A new technique allows the design of solid materia...

La Unidad de Chequeos de la Clínica sup...

El estudio realizado sobre una muestra significati...

Highlight

Interview with Dámaso Molero, general m...

by 3P Biopharmaceuticals

Dámaso Molero: “There are great opportunities in Latin America for ...

A hand-pick of latest VHIO research high...

by VHIO

​The BRCA1 and BRCA2 genes are crucial actors in the DNA damage resp...

Photos Stream